Professor Andrew Protheroe

Professor Andrew Protheroe is an Associate Professor of Uro-Oncology within the University of Oxford Department of Oncology at the Oxford Cancer and Haematology Centre. As a consultant medical oncologist he has specialised in managing urological cancer at Oxford since 2001. He qualified from St Thomas’s Hospital in London and after general medical training in London, trained in Oncology at St James’s University Hospital in Leeds. His PhD was in tumour immunology and the research was based at Leeds and the National Cancer Institute in Amsterdam as an Honorary ICRF Clinical Research fellow funded by a Northern and Yorkshire research award.

He has established and successfully runs a large portfolio of clinical studies in urological cancer (some Phase I mainly phase II and III) locally, with national and international collaboration, both as CI and PI. He has published over 100 peer-reviewed papers and is also the founding trustee of a urological cancer charity (UCARE) which is a local Oxfordshire based charity supporting and funding research and raising awareness within the Thames Valley. He was also instrumental in setting up the kidney cancer support group (FROG), and helped to develop the prostate and bladder cancer support groups and set up initiatives to support men with testicular cancer. Since 2014 he has been the co-clinical director for the NIHR Thames Valley and South Midlands Clinical Research Network which supports the infrastructure and facilitates clinical research throughout the area in all healthcare settings. He also is the national lead for the testicular 100, 000 genome project which looks to develop the understanding of the genetics involved in testicular cancer. Current Posts Associate Professor of Uro-Oncology University of Oxford Consultant Oncologist Oxford University Hospitals NHS Foundation Trust Lecturer in Medicine Worcester College University of Oxford Co-Clinical Director NIHR LCRN Thames Valley and South He specialises in managing and overseeing patients with urological cancer providing specialised expert care to patients and their families with: prostate cancer kidney cancer bladder cancer testicular / germ cell cancer covering all aspects of chemotherapy, hormonal therapy, immunotherapy, radium 223, growth inhibitors and novel therapies.